Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.

Praxis Precision Medicines Reports Positive Topline Results from PRAX-944 Phase 2a Study in Essential Tremor Patients Praxis Precision Medicines, Inc. Mon, May 9, 2022, 1:01 PM 6 min read ...

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies ...

Tuesday, Praxis Precision Medicines Inc . (NASDAQ:PRAX) shares received a boost as Truist Securities increased its price target for the company to $175 from $150, while maintaining a Buy rating.

(RTTNews) - Praxis Precision Medicines Inc. (PRAX) said that phase 2/3 Aria Study, which evaluated the efficacy and safety of PRAX-114 for monotherapy treatment of major depressive disorder (MDD ...